Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

@article{Colnot2003SafetyBP,
  title={Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck},
  author={David R. Colnot and J. D. Roos and Remco de Bree and Abraham J. Wilhelm and Jean Alain Kummer and Gertraud Hanft and K G Heider and Gerd Stehle and Gordon B J Snow and Guus A. M. S. van Dongen},
  journal={Cancer Immunology, Immunotherapy},
  year={2003},
  volume={52},
  pages={576-582}
}

• David R. Colnot, J. D. Roos, +7 authors Guus A. M. S. van Dongen
• Published 2003 in Cancer Immunology, Immunotherapy
• DOI:10.1007/s00262-003-0396-5

Previous studies have shown the potential of murine and chimeric anti-CD44v6 monoclonal antibodies (MAbs) for radioimmunotherapy (RIT) of head and neck squamous cell carcinoma (HNSCC). A limitation of these MAbs, however, appeared to be their immunogenicity. Therefore, humanized monoclonal antibody BIWA 4 (bivatuzumab), with an intermediate affinity for CD44v6, was recently selected. As a prelude to RIT, we evaluated the safety, tumor-targeting potential, pharmacokinetics, and immunogenicity of… CONTINUE READING

Save to Library

Create Alert

Cite

View on Springer